Vertex Pharmaceuticals Inc (VRTX)
397.48
-0.22
(-0.06%)
USD |
NASDAQ |
Apr 26, 16:00
397.43
-0.05
(-0.01%)
After-Hours: 20:00
Vertex Pharmaceuticals Net Income (Quarterly): 968.80M for Dec. 31, 2023
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
Date | Value |
---|---|
December 31, 2023 | 968.80M |
September 30, 2023 | 1.035B |
June 30, 2023 | 915.70M |
March 31, 2023 | 699.80M |
December 31, 2022 | 818.90M |
September 30, 2022 | 930.50M |
June 30, 2022 | 810.50M |
March 31, 2022 | 762.10M |
December 31, 2021 | 770.10M |
September 30, 2021 | 851.90M |
June 30, 2021 | 67.00M |
March 31, 2021 | 653.10M |
December 31, 2020 | 604.24M |
September 30, 2020 | 667.43M |
June 30, 2020 | 837.27M |
March 31, 2020 | 602.75M |
December 31, 2019 | 583.22M |
September 30, 2019 | 57.52M |
June 30, 2019 | 267.43M |
March 31, 2019 | 268.63M |
December 31, 2018 | 1.551B |
September 30, 2018 | 128.75M |
June 30, 2018 | 207.36M |
March 31, 2018 | 210.26M |
December 31, 2017 | 100.68M |
Date | Value |
---|---|
September 30, 2017 | -102.95M |
June 30, 2017 | 18.00M |
March 31, 2017 | 247.76M |
December 31, 2016 | 32.94M |
September 30, 2016 | -38.84M |
June 30, 2016 | -64.52M |
March 31, 2016 | -41.63M |
December 31, 2015 | -73.73M |
September 30, 2015 | -95.15M |
June 30, 2015 | -188.85M |
March 31, 2015 | -198.61M |
December 31, 2014 | -176.66M |
September 30, 2014 | -170.06M |
June 30, 2014 | -159.38M |
March 31, 2014 | -232.46M |
December 31, 2013 | 44.28M |
September 30, 2013 | -124.13M |
June 30, 2013 | -57.16M |
March 31, 2013 | -308.02M |
December 31, 2012 | -76.15M |
September 30, 2012 | -57.54M |
June 30, 2012 | -64.93M |
March 31, 2012 | 91.59M |
December 31, 2011 | 158.63M |
September 30, 2011 | 221.11M |
Net Income Definition
Net Income is the total amount of profit earned by a company. This metric boils down to the overall profit that is left from the revenue that a company receives after taking out various operational line items like cost of goods sold, income tax expense, SG&A expense, etc. Eventually, all companies would want to have a consistent positive and growing net income, so that this can be used for various purposes like reinvesting into the company, paying off debt, and potentially paying out dividends to shareholders.
Net Income (Quarterly) Range, Past 5 Years
57.52M
Minimum
Sep 2019
1.035B
Maximum
Sep 2023
679.14M
Average
762.10M
Median
Mar 2022
Net Income (Quarterly) Benchmarks
Amgen Inc | 767.00M |
Eli Lilly and Co | 2.190B |
Regeneron Pharmaceuticals Inc | 1.160B |
Alpine Immune Sciences Inc | 5.96M |
Moderna Inc | 217.00M |
Net Income (Quarterly) Related Metrics
Revenue (Quarterly) | 2.518B |
Total Expenses (Quarterly) | 1.562B |
EPS Diluted (Quarterly) | 3.71 |
Enterprise Value | 91.51B |
Gross Profit Margin (Quarterly) | 85.38% |
Profit Margin (Quarterly) | 38.48% |
Earnings Yield | 3.49% |
Operating Earnings Yield | 4.16% |
Normalized Earnings Yield | 3.859 |